Post on 25-Sep-2020
A Fantástica História da Imunoterapia do Câncer
Daniel Tabak
Centro de Tratamento Oncológico (CENTRON-RJ)
Diretor Centro de Transplante de Medula Óssea(INCA)1987-2004
Membro Titular,Academia Nacional de Medicina
Conflitos de Interesse
• Palestrante: Roche, Jannsen, Abbvie
• Consultoria científica : Roche, Janssen, Abbvie
A Fantástica História da Imunoterapia do Câncer
D'où venons-nous? Que sommes-nous? Où allons-nous?Paul Gauguin, 1897
ASCO 2017
2002
Demócrito (470-360 AC)
Jackson,R. Canadian Med Assoc.Journal, 1974,111,8271265 DC
Infecção e câncer
Gordon, S Eur. J. Immunol 2008
• Elie Metchnikof (1845-1916)
• Prêmio Nobel de Medicina em 1908
• Descreveu a fagocitose (imunidade inata)
1908
Paul Ehlich magischen kugeln,1890
“Imunização”
“Nature often gives us hints
to he profoundest secrets”
William B Coley,MD (1862-1936)
1888
John D Rockfeller,Jr e Elizabeth Dashiell
Coley,WB Am.J.Med.Sciences, May 1893
Mr. Fred Stein
William Coley’s Notes, Archives Cancer Research Institute
William Coley
James Ewing
James Douglas Cornelius Rhoads
Ernest Codman
1925:Surgeon-in-Chief,
Hospital of the Ruptured and Crippled NY,NY
Hospital of Special Surgery (150 anos em 2015)
New York Cancer Hospital
General Memorial Hospital
MSKCC
19281928
Helen Coley Nauts (1907-2001)
Cancer Research 1946;6:206-216
Archives Cancer Research Institute
1928Zbar,B JNCI 1970
1928
• 10 pacientes com tumores recidivados
• Instilação intravesical semanal x 6
• Hipersensibilidade tardia observada em 3-6 semanas
• 7/10 pacientes apresentaram resposta (redução ou
erradicação do tumor)
1928NEJM,1991
Anticorpos Monoclonais
Clin Cancer Res., 2014
Paul Ehlich,1890
1979
Laboratory of Molecular Biology, Cambridge
1979
1979
A Saga da Patente dos Anticorpos Monoclonais
1979
A Saga da Patente dos Anticorpos Monoclonais
1979
A Saga da Patente dos Anticorpos Monoclonais
1979
A Saga da Patente dos Anticorpos Monoclonais
Carta à Primeira Ministra Margaret Tatcher explicando como a patente foi perdida para os EUA
NIH Archives,
IL-2 trialsSteven A Rosenberg
JCO,1999
Rosenberg,S SITC,2015
www.biooncology.com
Ciclo Imunidade - Câncer
Célula
Apresentadora de
Antígenos
SIPULEUCEL-T
Figure 1
Cell 2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013)
SCIENCE * VOL. 271 * 22 MARCH 1996
Figure 1
Cell 2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013) Science,1996
PD-1 necessário para auto-tolerância
Ribas A Science 2018
RCC
Jama Oncology, 25/7/2019
Jama Oncology, 25/7/2019
Jama Oncology, 25/7/2019
Nobel Prize Medicine and Physiology 2018
Slide 27
Presented By Timothy Chan at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium
NEJM 2017
Science 8/6/2017
Science 8/6/2017
Science 8/6/2017
Nature Rev Clin Oncol, Fev 2015
Lin
fócit
o
Cancer,1949
Linfócitos infiltrantes de tumor estão associados com prognóstico favorável
Rosenberg,S,1985
Rosenberg,S AACR,2015
Rosenberg,S,Science,2015
Slide 7
Slide 8
Zelig Eshhar, Weizmann Institute,Israel
CAR T cell
84
CAR T CellsT cell
Viral DNA
Insertion
Tumor cell
Expression of
CAR
CAR T cells
multiply and
release cytokines
Tumor cell
apoptosis
CAR enables T cell to
recognize tumor cell
antigen
Antigen
Slide created by E Squared Communications
ASBMT2019
Emily’s story: Relapsed/refractory pediatric B-cell ALL
Tisagenlecleucel produz respostas em 81% na LLA-B pediátrica refratária e SLP 50% em 1 ano
ASBMT2019ASBMT2019
ASBMT2019ASBMT2019
Efficacy of 3 CAR T-cell products for Diffuse Large B-cell Lymphoma
Presented By Jeremy Abramson at 2019 ASCO Annual Meeting
Juna C ,Science 2018
Toxicidade de Células CAR-T
2002
Demócrito (470-360 ac)
Juna C ,Science 2018
Toxicidade de Células CAR-T
June, C ICML, Lugano 2019
June, C Science 2018
Slide 2
Slide 4
Brown CE et al. NEJM 2016
Brown CE et al. NEJM 2016
Mesothelin is a target antigen for solid tumors
Presented By Prasad Adusumilli at 2019 ASCO Annual Meeting
Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent
Presented By Prasad Adusumilli at 2019 ASCO Annual Meeting
Slide 16
Presented By Prasad Adusumilli at 2019 ASCO Annual Meeting
Limitações do uso de células CAR-T
• Capacidade de coletar e produzir o produto em pacientes
altamente tratados
• Disfunção das células T relacionadas à doença e terapia anterior
• Tempo de manufatura em portadores de linfoma
• Custo
Uma das respostas pode ser células CAR-T alogênicas...
NewScientist,2015
NewScientist,2015
Qasim W et al Science Transl Med 2017
NewScientist,2015ASH 2018
ASBMT2019
ASBMT2019
Model T Car 1920
Armored CARs
Presented By Jeremy Abramson at 2019 ASCO Annual Meeting
Armored CARs can enhance expansion <br />and persistence in vivo
IL-12 secreting anti-MUC-16ecto CAR T-cells Improves T-cell activation, expansion and ovarian tumor killing
Presented By Jeremy Abramson at 2019 ASCO Annual Meeting
2002
Demócrito (470-360 ac)
ASH,2017
Sivan A. Science 2015
Hampton, T Jama 2018
Science,2018
Jobin C. Science 2018
Antibiotics prescription decreases progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors
Slide 4
NYT,1975
Linacre Quarterly,2012
The Lancet, 1971
Mecanismos de Ação dos Vírus Oncolíticos
Bommarredy P Nature Ver Immunol 2018
Ann of Surgical Oncology,2006
Após injeção intratumoral
de metástase cutânea
Primary overall survival (OS) from OPTiM, a randomized phase 3 trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of unresected stage IIIB/C and IV melanoma
Presented By Howard Kaufman at 2014 ASCO Annual Meeting
Slide 8
Presented By Howard Kaufman at 2014 ASCO Annual Meeting
Slide 13
Presented By Howard Kaufman at 2014 ASCO Annual Meeting
Time to Response And Duration of Response
Presented By Howard Kaufman at 2016 ASCO Annual Meeting
Slide 19
28/10/2015
May 15,2016
ASCO2016
ASCO2016
2018
Cell,2017
Cell,2017
Cell,2017
2002
Demócrito (470-360 ac)
2002
Vírus MARABÁ (1983)
• Rabdovírus
• Associado à vesiculo estomatite
• Transmitido por moscas da areia
• Induz IFN após a infecção
• Pequena auto-imunidade pré-existente e pós exposição
• Prolifera exclusivamente no citoplasma (baixa genotoxicidade)
Marabá: vocábulo indígena (mayrabá) que significa filho do
estrangeiro com índia ou fruto da índia com o branco Wikipedia
2018
2018
2002
2002
CD3
CD3
The Lancet 2001https://www.sciencephoto.com
Alberto Montovani, NEJM,2018
Slide 32
November 2018
ICML-Lugano-2019
ICML-Lugano-2019
Forbes N .Nature Reviews Cancer 2010
Imunoterapia e Nanotecnologia
Chowdhury S et al. Nature Medicine May 2019
Chowdhury S et al. Nature Medicine May 2019
A Fantástica História da Imunoterapia do Câncer
D'où venons-nous? Que sommes-nous? Où allons-nous?Paul Gauguin, 1897
A revolution in cancer care<br />>2000 immunotherapy agents in development
Tang Ann Oncol 2018
Uma Revolução no Tratamento do Câncer
> 2000 agentes imunológicos em desenvolvimento
"Before Alamein we never had a victory. After Alamein we never had a defeat.”(1942)Após a vitória em El Alamein,1942
Linfócitos T
CâncerCélula Dendrítica
Macrófago
ASBMT2019ASBMT2019